Coupons & Offers
Highlights
composition with strength
Mebeverine (200mg)
description
Effective IBS symptom management, reduces abdominal pain and cramps, alleviates bloating and gas, supports regular bowel movements
key benefits
Treatment of Irritable bowel syndrome
side effects
Nausea, Dizziness, Headache, Abdominal pain, Loss of appetite, Hair loss, Bleeding, Fever and Sore throat
how to use
Take this medicine in the exact dose and duration as prescribed by your doctor
alcohol interaction
Safe
pregnancy interaction
Consult Your Doctor
lactation interaction
Consult Your Doctor
driving interaction
Safe
kidney interaction
Safe If Prescribed
liver interaction
Safe If Prescribed
Information
disclaimer
The contents and images displayed on this Platform are for informational purposes only and are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a registered medical practitioner with any questions you may have regarding a medical condition or the use of any product. Do not disregard professional medical advice or delay seeking it because of something you have read on this Platform.We intend to support, not replace, the doctor-patient relationship.
While we make every effort to ensure the information provided is accurate and up-to-date, we strongly recommend reviewing product labels, batch numbers, manufacturing and packaging details, as well as any warnings and usage instructions before using or consuming any product.
customer care details
In case of any issue, contact us
E-mail address: support@zeptonow.com
Seller Name
Drogheria Sellers Private Limited
Seller Address
Brigade IRV, 9th & 10th Floors, Nallurhalli, White Field, Bangalore, Banglore, Karnataka, India, 560066 For Support ReachOut : support+drogheria@zeptonow.com
Pharmacy License No.
MH-TZ1-581061, MH-TZ1-581062
Manufacturer or Marketer Name
Zydus Cadila
Manufacturer or Marketer Address
208, Okhla Industrial Estate, Phase III, New Delhi - 110020
Country of Origin
India
Shelf Life
24 months
Expires on or after
December 2026
